{
    "organizations": [],
    "uuid": "32f7e54522a851fa3cb636a8760ee3daa8f4803b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-arqule-and-basilea-enter-into-excl/brief-arqule-and-basilea-enter-into-exclusive-license-agreement-for-derazantinib-idUSFWN1RU0SE",
    "ord_in_thread": 0,
    "title": "BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17 (Reuters) - ArQule Inc:\n* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA\n* ARQULE INC - UNDER TERMS OF AGREEMENT, ARQULE WILL RECEIVE AN UPFRONT PAYMENT OF $10 MILLION\n* ARQULE INC - ARQULE ELIGIBLE TO RECEIVE UP TO $336 MILLION INCLUDING UPFRONT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS\n* ARQULE - UNDER CERTAIN CIRCUMSTANCES, CO MAY HAVE OPPORTUNITY TO PROMOTE DERAZANTINIB IN U.S. DIRECTLY\n* ARQULE - ALSO ENTITLED TO RECEIVE STAGGERED SINGLE-DIGIT TO DOUBLE-DIGIT ROYALTIES ON NET SALES UPON COMMERCIALIZATION\n* ARQULE - BASILEA WILL BE RESPONSIBLE FOR ALL COSTS AND EXPENSES OF DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION IN ITS TERRITORY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-17T19:03:00.000+03:00",
    "crawled": "2018-04-17T15:29:27.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "arqule",
        "inc",
        "arqule",
        "basilea",
        "enter",
        "exclusive",
        "license",
        "agreement",
        "derazantinib",
        "u",
        "eu",
        "japan",
        "rest",
        "world",
        "excluding",
        "greater",
        "china",
        "arqule",
        "inc",
        "term",
        "agreement",
        "arqule",
        "receive",
        "upfront",
        "payment",
        "million",
        "arqule",
        "inc",
        "arqule",
        "eligible",
        "receive",
        "million",
        "including",
        "upfront",
        "regulatory",
        "commercial",
        "milestone",
        "payment",
        "arqule",
        "certain",
        "circumstance",
        "co",
        "may",
        "opportunity",
        "promote",
        "derazantinib",
        "directly",
        "arqule",
        "also",
        "entitled",
        "receive",
        "staggered",
        "royalty",
        "net",
        "sale",
        "upon",
        "commercialization",
        "arqule",
        "basilea",
        "responsible",
        "cost",
        "expense",
        "development",
        "manufacture",
        "commercialization",
        "territory",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}